Antibody-drug conjugates as multimodal therapies against hard-to-treat cancers

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Antibody-drug conjugates (ADCs) represent a multimodal strategy for targeted delivery of cytotoxic agents to tumors.
• Advances in antibody engineering and potent cytotoxic drugs enable novel ADC designs for chemotherapy-resistant cancers.

Purpose of the Study:

• To review recent advancements in ADC therapies for challenging cancers.
• To focus on design considerations for ADC efficacy in breast cancer and glioblastoma multiforme.
• To highlight challenges in correlating in vitro and in vivo performance for clinical translation.

Main Methods:

• Literature review of antibody engineering and conjugation chemistries.
• Analysis of ADC design principles and quality attributes.
• Examination of clinical translation challenges and future directions.

Main Results:

• ADCs show promise for targeted cancer therapy, but balancing efficacy and toxicity remains a key challenge.
• Innovations in conjugation chemistry and antibody engineering are crucial for overcoming resistance.
• A comprehensive in vitro-in vivo correlation is needed to accelerate clinical translation.

Conclusions:

• ADCs are a powerful tool for next-generation cancer therapies, addressing unmet clinical needs.
• Optimizing ADC design and quality attributes is critical for successful clinical translation.
• Further research integrating engineering advancements and industrial insights is essential.